Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

Journal of medicinal chemistry - 14 Aug 2008

Kozísek Milan, Cígler Petr, Lepsík Martin, Fanfrlík Jindrich, Rezácová Pavlína, Brynda Jirí, Pokorná Jana, Plesek Jaromír, Grüner Bohumír, Grantz Sasková Klára, Václavíková Jana, Král Vladimír, Konvalinka Jan

Abstract excerpt

HIV protease (PR) is a prime target for rational anti-HIV drug design. We have previously identified icosahedral metallacarboranes as a novel class of nonpeptidic protease inhibitors. Now we show that substituted metallacarboranes are potent and specific competitive inhibitors of drug-resistant HIV PRs prepared either by site-directed mutagenesis or cloned from HIV-positive patients. Molecular modeling explains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Boron Compounds
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Metals

Share to Molecular Structure

Source

Identifiers

PMID: 18598016
DOI: 10.1021/jm8002334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.PMID 18598016Read ↗

Molecular docking-based screening for novel inhibitors of the human immunodeficiency virus type 1 protease that effectively reduce the viral replication in human cellsSemantic proximity Read ↗

Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV ProteaseSemantic proximity Read ↗

HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionSemantic proximity Read ↗

Novel Wild Type and Mutate HIV-1 Protease Inhibitors Containing Heteroaryl Carboxamides in P2: Synthesis, Biological and ADME EvaluationsSemantic proximity Read ↗

Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.Semantic proximity Read ↗

A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsidSemantic proximity Read ↗

In silico screening of indinavir-based compounds targeting proteolytic activity in HIV PR: binding pocket fit approachSemantic proximity Read ↗

Combating susceptibility to drug resistance: lessons from HIV-1 protease.Semantic proximity Read ↗

Identification of Structural Mechanisms of HIV-1 Protease Specificity Using Computational Peptide Docking: Implications for Drug ResistanceSemantic proximity Read ↗

Discovery of Entry Inhibitors for HIV-1 via a New De Novo Protein Design FrameworkSemantic proximity Read ↗

Rational Approach to AIDS Drug Design Through Structural BiologySemantic proximity Read ↗

Design of novel HIV-1 protease inhibitors with favorable oral properties using a virtual screening and lead optimization approachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.